An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

Abstract Background Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases. The purpose of this study is to explore how commonly utilized antiretroviral therapy (tenofovir disoproxil fumarate/lamivudine [TDF/3TC] and a...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Stephen I. Walimbwa, Julian P. Kaboggoza, Catriona Waitt, Pauline Byakika-Kibwika, Antonio D’Avolio, Mohammed Lamorde
Formato:	article
Lenguaje:	EN
Publicado:	BMC 2021
Materias:	Remdesivir COVID-19 Ebola HIV Atazanavir Ritonavir Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/26bf941c00ff42d0b23cc8cb48487595
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:26bf941c00ff42d0b23cc8cb48487595
record_format	dspace
spelling	oai:doaj.org-article:26bf941c00ff42d0b23cc8cb484875952021-11-28T12:28:20ZAn open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)10.1186/s13063-021-05752-11745-6215https://doaj.org/article/26bf941c00ff42d0b23cc8cb484875952021-11-01T00:00:00Zhttps://doi.org/10.1186/s13063-021-05752-1https://doaj.org/toc/1745-6215Abstract Background Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases. The purpose of this study is to explore how commonly utilized antiretroviral therapy (tenofovir disoproxil fumarate/lamivudine [TDF/3TC] and atazanavir/ritonavir [ATV/r]) influence plasma and intracellular concentrations of remdesivir. Methods This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions between remdesivir and TDF/3TC (Study A, crossover design) or TDF/3TC plus ATV/r (Study B). Healthy volunteers satisfying study entry criteria will be enrolled in the study and randomized to either Study A; N=16 (Sequence 1 or Sequence 2) or Study B; N=8. Participants will receive standard adult doses of antiretroviral therapy for 7 days and a single 200mg remdesivir infusion administered over 60 min. Pharmacokinetic blood sampling will be performed relative to the start of remdesivir infusion; predose (before the start of remdesivir infusion) and 30 min after the start of remdesivir infusion. Additional blood samples will be taken at 2, 4, 6, 12, and 24 h after the end of remdesivir infusion. Discussion This study will characterize the pharmacokinetics of remdesivir from a typical African population in whom clinical use is anticipated. Furthermore, this study will deliver pharmacokinetic datasets for remdesivir drug concentrations and demographic characteristics which could support pharmacometric approaches for simulation of remdesivir treatment regimens in patients concurrently using tenofovir/lamivudine and/or atazanavir/ritonavir. Trial registration ClinicalTrials.gov NCT04385719 . Registered 13 May 2020.Stephen I. WalimbwaJulian P. KaboggozaCatriona WaittPauline Byakika-KibwikaAntonio D’AvolioMohammed LamordeBMCarticleRemdesivirCOVID-19EbolaHIVAtazanavirRitonavirMedicine (General)R5-920ENTrials, Vol 22, Iss 1, Pp 1-13 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Remdesivir COVID-19 Ebola HIV Atazanavir Ritonavir Medicine (General) R5-920
spellingShingle	Remdesivir COVID-19 Ebola HIV Atazanavir Ritonavir Medicine (General) R5-920 Stephen I. Walimbwa Julian P. Kaboggoza Catriona Waitt Pauline Byakika-Kibwika Antonio D’Avolio Mohammed Lamorde An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
description	Abstract Background Remdesivir is a novel broad-spectrum antiviral therapeutic with activity against several viruses that cause emerging infectious diseases. The purpose of this study is to explore how commonly utilized antiretroviral therapy (tenofovir disoproxil fumarate/lamivudine [TDF/3TC] and atazanavir/ritonavir [ATV/r]) influence plasma and intracellular concentrations of remdesivir. Methods This is an open-label, randomized, fixed sequence single intravenous dosing study to assess pharmacokinetic interactions between remdesivir and TDF/3TC (Study A, crossover design) or TDF/3TC plus ATV/r (Study B). Healthy volunteers satisfying study entry criteria will be enrolled in the study and randomized to either Study A; N=16 (Sequence 1 or Sequence 2) or Study B; N=8. Participants will receive standard adult doses of antiretroviral therapy for 7 days and a single 200mg remdesivir infusion administered over 60 min. Pharmacokinetic blood sampling will be performed relative to the start of remdesivir infusion; predose (before the start of remdesivir infusion) and 30 min after the start of remdesivir infusion. Additional blood samples will be taken at 2, 4, 6, 12, and 24 h after the end of remdesivir infusion. Discussion This study will characterize the pharmacokinetics of remdesivir from a typical African population in whom clinical use is anticipated. Furthermore, this study will deliver pharmacokinetic datasets for remdesivir drug concentrations and demographic characteristics which could support pharmacometric approaches for simulation of remdesivir treatment regimens in patients concurrently using tenofovir/lamivudine and/or atazanavir/ritonavir. Trial registration ClinicalTrials.gov NCT04385719 . Registered 13 May 2020.
format	article
author	Stephen I. Walimbwa Julian P. Kaboggoza Catriona Waitt Pauline Byakika-Kibwika Antonio D’Avolio Mohammed Lamorde
author_facet	Stephen I. Walimbwa Julian P. Kaboggoza Catriona Waitt Pauline Byakika-Kibwika Antonio D’Avolio Mohammed Lamorde
author_sort	Stephen I. Walimbwa
title	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
title_short	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
title_full	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
title_fullStr	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
title_full_unstemmed	An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)
title_sort	open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in ugandan healthy volunteers (remtlar)
publisher	BMC
publishDate	2021
url	https://doaj.org/article/26bf941c00ff42d0b23cc8cb48487595
work_keys_str_mv	AT stepheniwalimbwa anopenlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT julianpkaboggoza anopenlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT catrionawaitt anopenlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT paulinebyakikakibwika anopenlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT antoniodavolio anopenlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT mohammedlamorde anopenlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT stepheniwalimbwa openlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT julianpkaboggoza openlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT catrionawaitt openlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT paulinebyakikakibwika openlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT antoniodavolio openlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar AT mohammedlamorde openlabelrandomizedsingleintravenousdosingstudytoinvestigatetheeffectoffixeddosecombinationsoftenofovirlamivudineoratazanavirritonavironthepharmacokineticsofremdesivirinugandanhealthyvolunteersremtlar
_version_	1718407940667342848

An open-label, randomized, single intravenous dosing study to investigate the effect of fixed-dose combinations of tenofovir/lamivudine or atazanavir/ritonavir on the pharmacokinetics of remdesivir in Ugandan healthy volunteers (RemTLAR)

Ejemplares similares